Columbia Laboratories, Inc. Release: Vaginal Progesterone is Equally Effective in Achieving Pregnancy Outcomes as Injectable Progesterone in Donor Egg Cycles

LIVINGSTON, N.J. & RANCHO MIRAGE, Calif.--(BUSINESS WIRE)--A retrospective analysis of anonymous oocyte (egg) donation cycles, comparing the pregnancy outcomes between vaginally-administered progesterone versus intramuscular (IM) progesterone injections, demonstrates that vaginally-administered progesterone and IM progesterone achieve equal pregnancy outcomes, according to data presented by Brian Berger, MD, Boston IVF, at the Pacific Coast Reproductive Society annual meeting in Rancho Mirage, CA. The retrospective study was supported by a grant from Columbia Laboratories, Inc. (NASDAQ:CBRX).